[The regulatory framework for complementary and alternative medicines in Europe].
Werner Knöss1, F Stolte, K Reh
1Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger Allee 3, Bonn, BRD. knoess@bfarm.de
Summary
Medicinal products from complementary and alternative medicine are integrated into Germany's healthcare. European regulations harmonize herbal, traditional, and homeopathic medicinal products, influencing future market development.
Area of Science:
- Pharmacology
- Regulatory Affairs
- Public Health
Context:
- Complementary and alternative medicine (CAM) products are integral to Germany's healthcare system.
- Herbal, homeopathic, and anthroposophic medicines enjoy high public acceptance.
- National legislation in Germany acknowledges the unique nature of CAM products.
Purpose:
- To outline the regulatory status of CAM medicinal products within the European Union.
- To detail the harmonization efforts for herbal, traditional, and homeopathic medicinal products.
- To analyze the impact of European directive 2001/83/EC on the CAM market.
Summary:
- The German Medicines Act mandates consideration of CAM product characteristics.
- European directive 2001/83/EC defines the regulatory framework for herbal, traditional, and homeopathic medicinal products.
- The Committee for Herbal Medicinal Products (HMPC) and a working group of Heads of Medicines Agencies facilitate harmonization.
Impact:
- Harmonization through directive 2001/83/EC implementation will significantly shape the European CAM market.
- Standardized regulations are expected to foster growth and integration of CAM products.
- This regulatory evolution impacts manufacturers, healthcare providers, and consumers of CAM therapies.
Related Concept Videos
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:28Global Regulatory Systems
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...